Drug profile · INN
eptinezumab
VYEPTI
eptinezumab (VYEPTI) is a calcitonin gene-related peptide inhibitor.
EMA: approved TGA: approved Nervous system (N02) N02CD
Patents linked 0
Pipeline programs 5
News articles 1
Drug details — eptinezumab
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
eptinezumab (VYEPTI) is a calcitonin gene-related peptide inhibitor.
Key facts
INN eptinezumab
Brand VYEPTI
Mechanism Calcitonin gene-related peptide inhibitor
Target Calcitonin gene-related peptide
Therapeutic class Nervous system (N02)
ATC code N02CD
Mechanism of action
Calcitonin gene-related peptide inhibitor
Primary target: Calcitonin gene-related peptide
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eptinezumab?
eptinezumab (VYEPTI) is a calcitonin gene-related peptide inhibitor.
What is the brand name for eptinezumab?
VYEPTI is a marketed brand name for eptinezumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.